Syndax Pharmaceuticals Inc - 8-K Filing
Syndax Pharmaceuticals announces Q3 2026 financial results and appointment of Aaron A. Ondrey as new CFO. (Items: 2.02 Results of Operations and Financial Condition, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Offi, 9.01 Financial Statements and Exhibits)
Tickers: $SNDX